SEI Investments’s Ginkgo Bioworks DNA Stock Holding History

SEI Investments’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,974	Closed	-$26.4K	–	2706
2024 Q2	$26.4K	Sell	1,974 -46	-2%	-$1.37K	﹤0.01%	2623
2024 Q1	$93.7K	Sell	2,020 -30	-1%	-$1.55K	﹤0.01%	2508
2023 Q4	$139K	Buy	2,050 +909	+80%	+$55.7K	﹤0.01%	2489
2023 Q3	$82.6K	Hold	1,141	–	–	﹤0.01%	2530
2023 Q2	$84.9K	Sell	1,141 -71	-6%	-$4.2K	﹤0.01%	2586
2023 Q1	$64.5K	Buy	+1,212	New	+$76.8K	﹤0.01%	2611

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SEI Investments's DNA Position: Q3 2024 in Review

SEI Investments sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 1,974 shares — an estimated $26.4K sold.

SEI Investments first reported a position in DNA in Q1 2023 and held it in 6 quarters. The position peaked at $139K in Q4 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

SEI Investments reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
SEI Investments sold 1,974 Ginkgo Bioworks shares in Q3 2024, an estimated $26.4K.
SEI Investments first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 6 quarters.
SEI Investments's Ginkgo Bioworks position peaked at $139K in Q4 2023.
159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on SEI Investments's 13F filing for Q3 2024, filed 12 Nov 2024.